Neurology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Figures Only
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow CME: Take the course for this article:
 Volume 64, Number 10, May 24, 2005
Right arrow Correspondence:
Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when Correspondence are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Chung, K. A.
Right arrow Articles by Nutt, J. G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Chung, K. A.
Right arrow Articles by Nutt, J. G.
Related Collections
Right arrow Parkinson's disease/Parkinsonism
Right arrow All Clinical trials
Right arrow Clinical trials Observational study (Cohort, Case control)
NEUROLOGY 2005;64:1797-1798
© 2005 American Academy of Neurology
Brief Communications

Short-term paroxetine treatment does not alter the motor response to levodopa in PD

Kathryn A. Chung, MD, Nichole E. Carlson, PhD and John G. Nutt, MD

From the Oregon Health and Science University, Portland, OR.

Address correspondence and reprint requests to Dr. Kathryn Chung, Oregon Health and Science University, 3181 SW Sam Jackson Park Road, OP32, Portland, OR 97239-3098; e-mail: chungka{at}ohsu.edu

The authors examined the motor effects of 2 weeks of paroxetine, a serotonin reuptake inhibitor (SSRI), and placebo on responses to 2-hour levodopa infusions in 14 subjects with Parkinson disease. Paroxetine did not affect tapping scores or dyskinesia. Baseline walking speed (preinfusion) increased on paroxetine, often associated with an increased subjective perception of worsened balance.

Supported in part by Veteran’s Administration Parkinson’s Disease Research, Education and Clinical Center (PADRECC) NIH grant 5-R01-NS021062 and PHS grant 5-M01-RR000334.

Dr. Chung has nothing to disclose. Dr. Nutt has received unrestricted educational grants and honoraria from GlaxoSmithKline.

Received August 30, 2004. Accepted in final form February 9, 2005.






HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2005 by AAN Enterprises, Inc.